JVPLabs (JRAS Medical Inc.)

Transforming Congestive Heart Failure (CHF) Management JVPLabs is a pre-FDA medical device company redefining how CHF is monitored and managed—both in the hospital and, ultimately, in the home. Today, CHF is the single largest cost driver for Medicare. Patients often require extended hospital stays, with 57% remaining hospitalized for more than 3–14 days. Yet, 50% are discharged with missed signs of congestion—a significant driver of high readmission rates, with 25% of patients readmitted within 30 days. Our Solution: JVPLabs enables patient monitoring and remote patient monitoring companies to deliver a complete CHF solution. Our non-invasive device automates the gold-standard assessment of Jugular Venous Pressure (JVP)—a critical, yet historically underutilized, measure of cardiac filling pressure. Using proprietary optical imaging and algorithms, we provide accurate, objective data at the bedside and, in the future, in the home. Key Benefits: • Provides an objective measure of cardiac filling pressures • Addresses key barriers to wide-scale adoption by being non-invasive and cost-effective • Seamless integration into hospital workflows for early intervention, discharge planning, and quality monitoring • Simple, automated measurements—proven easy to use, even for elderly patients With 80% of CHF care delivered outside of specialist cardiology, JVPLabs is a game changer. Our technology empowers less experienced clinicians and caregivers to leverage this critical tool for CHF monitoring, enabling them to deliver specialist-quality care across the continuum. If you would like more information or want to get involved in changing patient care for CHF—whether as an employee, clinical collaborator, or commercial partner—please contact us: [email protected] www.jvplabs.com

• Employees 15
• Founded 2016